10-Q: Veru Inc. Reports Positive Phase 2b Results for Enobosarm in Obesity Program and Provides Financial Update

Veru Inc. announces positive topline results from its Phase 2b QUALITY clinical study of enobosarm in obese or overweight older patients and provides a financial update in its latest 10-Q filing.

Summary

• Veru Inc., a biopharmaceutical company, filed its 10-Q for the quarter ended March 31, 2025.
• The company is focused on developing novel medicines for cardiometabolic and inflammatory diseases, including enobosarm for obesity and sabizabulin for cardiovascular disease.
• A Phase 2b QUALITY clinical study of enobosarm met its primary endpoint, showing a statistically significant benefit in preserving lean body mass in older patients receiving semaglutide.
• Enobosarm treatment also resulted in greater loss of fat mass compared to placebo.
• The company plans to request an End of Phase 2 meeting with the FDA to discuss a Phase 3 clinical program for enobosarm.
• Veru is also exploring the clinical development of sabizabulin for the treatment of inflammation in atherosclerotic cardiovascular disease and had a pre-IND meeting with the FDA.
• The company sold its FC2 business on December 30, 2024, for $18.0 million, resulting in net proceeds of approximately $16.3 million and a loss on sale of $4.2 million.
• The company recorded a gain on extinguishment of debt of $8.6 million related to the termination of the Residual Royalty Agreement in connection with the FC2 Business Sale.
• For the three months ended March 31, 2025, research and development expenses were $3.9 million, and selling, general and administrative expenses were $5.2 million.
• The company recorded a net loss from discontinued operations of $49,000 for the three months ended March 31, 2025.
• Cash, cash equivalents, and restricted cash totaled $20.0 million as of March 31, 2025.
• The company estimates that its current cash and cash equivalents are insufficient to fund operating, investing, and financing cash flow needs for the twelve months subsequent to the issuance date of these financial statements, raising substantial doubt about its ability to continue as a going concern.
• Veru is seeking additional financing through public or private equity offerings, debt financing, and other capital sources.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. Positive clinical trial results are offset by financial concerns and uncertainties regarding future funding and debt repayment.

Positives

• Positive topline results from the Phase 2b QUALITY clinical study for enobosarm.
• Enobosarm shows potential to improve body composition by augmenting fat loss and preventing muscle loss.
• The company is planning to request an End of Phase 2 meeting with the FDA to discuss a Phase 3 clinical program for enobosarm.
• The company is exploring the clinical development of sabizabulin for the treatment of inflammation in atherosclerotic cardiovascular disease.
• The company had a pre-IND meeting with the FDA regarding sabizabulin for atherosclerotic disease.
• The sale of the FC2 business generated net proceeds of approximately $16.3 million.
• The company recorded a gain on extinguishment of debt of $8.6 million related to the termination of the Residual Royalty Agreement.

Negatives

• The company estimates that its current cash and cash equivalents are insufficient to fund operating, investing, and financing cash flow needs for the twelve months subsequent to the issuance date of these financial statements, raising substantial doubt about its ability to continue as a going concern.
• The company has incurred net losses in recent fiscal years and expects to continue to incur losses for the foreseeable future.
• The company recorded a loss on sale of the FC2 business of $4.2 million.
• There is uncertainty as to whether and when the company will receive any future installment payments of purchase price under the ONCO Promissory Notes or sales milestone payments under the Asset Purchase Agreement, and there is a risk of a future default by ONCO in performing its payment obligations.
• The company is subject to significant payment obligations pursuant to the resolution of a dispute with a supplier.

Risks

• Potential delays in clinical trials and regulatory approvals.
• The need to secure significant funding to advance drug candidates.
• Competition from existing and new competitors.
• Risks related to intellectual property and potential infringement claims.
• The company's ability to continue as a going concern is uncertain.
• The company may not receive any additional payments from ONCO in connection with the sale of ENTADFI assets.
• The company is subject to significant payment obligations pursuant to the resolution of a dispute with a supplier.

Future Outlook

The company plans to request an End of Phase 2 meeting with the FDA to discuss a Phase 3 clinical program for enobosarm and is exploring the clinical development of sabizabulin for the treatment of inflammation in atherosclerotic cardiovascular disease.

Management Comments

• The Phase 2b QUALITY study is the first human study to report the effects of a muscle preservation drug candidate on body composition in older patients who have obesity or are overweight and receiving a GLP-1 receptor agonist.
• Enobosarm represents a novel drug that improves GLP-1 RA therapy resulting in tissue selective quality weight reduction.

Industry Context

The document highlights the growing market for obesity treatments, particularly GLP-1 receptor agonists, and the unmet need for drugs that can mitigate muscle loss associated with these therapies. It also discusses the role of inflammation in atherosclerotic cardiovascular disease and the potential for anti-inflammatory therapies.

Comparison to Industry Standards

• The document references third-party clinical trials evaluating currently approved GLP-1 RA in obese patients, noting that 20-50% of the total weight loss reported was attributable to lean mass (muscle) loss.
• The document compares sabizabulin to colchicine, an FDA-approved anti-inflammatory drug for cardiovascular events, highlighting sabizabulin's potential advantages in terms of safety and drug-drug interactions.
• The document references the SCOT-HEART Trial (Scottish Computed Tomography of the HEART) and its use of low attenuation plaque volume (LAPV) as a predictor of cardiovascular events.
• The document references CRESTOR (rosuvastatin calcium) tablets package insert and NIASPAN (niacin) extended release tablets package insert as examples of FDA drug approvals from CAD atherosclerosis clinical studies using coronary or carotid artery imaging as a primary endpoint to support the indication for the treatment to slow the progression or promote regression of atherosclerotic disease.

Legal Proceedings

• The company is involved in several shareholder lawsuits related to public statements about sabizabulin as a treatment for COVID-19.
• The company is unable to estimate potential losses, if any, related to the Shareholder Litigation.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees face uncertainty due to the company's financial situation and potential need for cost reductions.
• Patients may benefit from the development of new treatments for obesity and cardiovascular disease.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• Request an End of Phase 2 meeting with the FDA to discuss a Phase 3 clinical program for enobosarm.
• Complete the Phase 2b extension clinical study and report topline efficacy and safety results.
• Submit a new IND for sabizabulin for the proposed indication by the first half of calendar 2026.
• Secure additional financing through public or private equity offerings, debt financing, and other capital sources.

Key Dates

Keywords

enobosarm, sabizabulin, clinical trial, obesity, cardiovascular, FDA, financial results, Veru Inc, 10-Q, biopharmaceutical